TABLE 3.
Transfusions and BTH Episodes in the 12-Month Post-Index Period
| Outcome | Eculizumab (n = 34) | Ravulizumab (n = 52) |
|---|---|---|
| Members with transfusions, n (%) | ||
| No transfusions | 16 (47.1) | 35 (67.3) |
| 1-3 transfusions | 8 (23.5) | 8 (15.4) |
| ≥ 4 transfusion | 10 (29.4) | 9 (17.3) |
| Members with BTH | ||
| No episodes, n (%) | 24 (70.6) | 45 (86.5) |
| 1 episode, n (%) | 4 (11.8) | 2 (3.8) |
| 2 episodes, n (%) | 2 (5.9) | 2 (3.8) |
| ≥ 3 episodes, n (%) | 4 (11.8) | 3 (5.8) |
| Number of BTH episodes, mean (SD) | 0.9 (2.2) | 0.5 (2.0) |
| Members with ED visit | ||
| ≥ 1 visit, n (%) | 13 (38.2) | 12 (23.1) |
| Number of ED visits, mean (SD) | 1.0 (1.6) | 0.7 (1.8) |
| Members with hospitalization/inpatient stay | ||
| ≥ 1 visit, n (%) | 13 (38.2) | 11 (21.2) |
| Number of hospitalizations, mean (SD) | 1.1 (2.1) | 0.5 (1.1) |
BTH = breakthrough hemolysis; ED = emergency department.